The Department of Health and Human Services Food and Drug Administration (FDA) awarded an Indefinite Delivery Contract under the BEST (Biologics Effectiveness and Safety) Initiative to CVS Health Clinical Trial Services LLC, a subsidiary of CVS Health Corporation. The contract, with a $50 million ceiling value and performance period through September 2025, is for the procurement of data sources to support the FDA's surveillance of biologics.
Two task orders have been awarded to date under this IDIQ contract. The first, valued at $24.5 million, is for CVS Health Clinical Trial Services to provide data sources and conduct analyses to enhance post-market safety monitoring of biologics. The second, worth $1.7 million, is specifically for the provision of healthcare patient data to support the FDA's BEST initiatives. Both task orders utilize a time and materials pricing structure and will be performed in Hartford, Connecticut. This procurement was issued as full and open competition with no set-aside designations.
Generated 12/24/24, 9:17 AM